Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

@article{Walrand2011ExperimentalFS,
  title={Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts},
  author={St{\'e}phan Walrand and Raffaella Barone and Stanislas Pauwels and François Jamar},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2011},
  volume={38},
  pages={1270-1280}
}
PurposeThe aim of this study was to retrospectively evaluate whether the red marrow (RM) takes up 111In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe1-octreotide and 86Y-DOTATOC and to assess the correlation between the RM absorbed doses and platelet count reduction as a biological dose estimate.MethodsData from 12 patients who underwent at 24 h p.i. high statistics 111In single photon emission computed tomography (SPECT) and 86Y positron emission tomography (PET) acquisitions of the chest… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2011
VIEW 5 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND

86Y-DOTATOC uptake in red marrow is not routinely visible

  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals.

Y Yonekura, S Mattsson, +9 authors P Zanzonico
  • Annals of the ICRP
  • 2019

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2017
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2008
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2005
VIEW 5 EXCERPTS

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

Cecilia Hindorf, Gerhard Glatting, Carlo Chiesa, Ola Lindén, G. Belben Flux
  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

a possible role of plasma protein binding

R Barone, S Walrand, P Leveque, S Pauwels, analogues Jamar F. Red marrow toxicity after therapy with ra somatostatin
  • Eur J Nucl Med 2003;30:S232. Eur J Nucl Med Mol Imaging
  • 2011
VIEW 1 EXCERPT